BR112017014914A2 - terapia combinada para hipertensão pulmonar - Google Patents
terapia combinada para hipertensão pulmonarInfo
- Publication number
- BR112017014914A2 BR112017014914A2 BR112017014914A BR112017014914A BR112017014914A2 BR 112017014914 A2 BR112017014914 A2 BR 112017014914A2 BR 112017014914 A BR112017014914 A BR 112017014914A BR 112017014914 A BR112017014914 A BR 112017014914A BR 112017014914 A2 BR112017014914 A2 BR 112017014914A2
- Authority
- BR
- Brazil
- Prior art keywords
- pulmonary hypertension
- combined therapy
- bmpr2
- combination therapy
- activator
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 3
- 208000002815 pulmonary hypertension Diseases 0.000 title abstract 3
- 239000012190 activator Substances 0.000 abstract 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229960001967 tacrolimus Drugs 0.000 abstract 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente invenção refere-se a composições e métodos para o tratamento da hipertensão pulmonar utilizando terapia combinada. a terapia combinada compreende um composto que aumenta a sinalização de bmpr2 (ativador de bmpr2) em combinação com pelo menos outro agente para o tratamento de hipertensão pulmonar. em certos aspectos, o ativador de bmpr2 pode ser tacrolimus ou um solvato, sal ou pró-fármaco do mesmo farmaceuticamente aceitável.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562103020P | 2015-01-13 | 2015-01-13 | |
US62/103,020 | 2015-01-13 | ||
PCT/US2016/012694 WO2016114993A1 (en) | 2015-01-13 | 2016-01-08 | Combination therapy for pulmonary hypertension |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112017014914A2 true BR112017014914A2 (pt) | 2018-03-13 |
BR112017014914B1 BR112017014914B1 (pt) | 2023-11-14 |
Family
ID=56406244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017014914-1A BR112017014914B1 (pt) | 2015-01-13 | 2016-01-08 | Uso de uma combinação de tacrolimus e um segundo agente ativo eficaz no tratamento ou prevenção da hipertensão pulmonar |
Country Status (12)
Country | Link |
---|---|
US (3) | US20180325875A1 (pt) |
EP (1) | EP3244968B1 (pt) |
JP (1) | JP6890540B2 (pt) |
KR (1) | KR102569428B1 (pt) |
CN (1) | CN107427698A (pt) |
AU (1) | AU2016207046B2 (pt) |
BR (1) | BR112017014914B1 (pt) |
CA (1) | CA2973114C (pt) |
IL (1) | IL253325A0 (pt) |
MX (1) | MX2017009110A (pt) |
NZ (1) | NZ733451A (pt) |
WO (1) | WO2016114993A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
EP3554507A1 (en) | 2016-12-14 | 2019-10-23 | Respira Therapeutics, Inc. | Methods and compositions for treatment of pulmonary hypertension and other lung disorders |
CN112569357B (zh) * | 2019-09-30 | 2023-03-28 | 深圳奥萨制药有限公司 | 双重内皮素受体拮抗剂与利尿剂的组合物 |
IL293271A (en) * | 2019-11-29 | 2022-07-01 | Actelion Pharmaceuticals Ltd | Methods for treating pulmonary artery hypertension |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110171193A1 (en) * | 2008-06-12 | 2011-07-14 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating pulmonary hypertension |
PT2704711T (pt) * | 2011-05-02 | 2021-03-02 | Univ Leland Stanford Junior | Utilização de fk506 para o tratamento da hipertensão arterial pulmonar |
AU2012252165A1 (en) | 2011-05-09 | 2013-03-21 | Cambridge Enterprise Limited | Methods of modulating micrornas in the treatment of pulmonary arterial hypertension |
EP2827849A4 (en) * | 2012-03-23 | 2015-11-18 | Univ Leland Stanford Junior | TREATMENT OF PULMONARY HYPERTONIA WITH LEUKOTRIENHEMMERN |
-
2016
- 2016-01-08 MX MX2017009110A patent/MX2017009110A/es unknown
- 2016-01-08 WO PCT/US2016/012694 patent/WO2016114993A1/en active Application Filing
- 2016-01-08 BR BR112017014914-1A patent/BR112017014914B1/pt active IP Right Grant
- 2016-01-08 KR KR1020177022273A patent/KR102569428B1/ko active IP Right Grant
- 2016-01-08 CN CN201680015289.1A patent/CN107427698A/zh active Pending
- 2016-01-08 US US15/543,510 patent/US20180325875A1/en not_active Abandoned
- 2016-01-08 AU AU2016207046A patent/AU2016207046B2/en active Active
- 2016-01-08 CA CA2973114A patent/CA2973114C/en active Active
- 2016-01-08 EP EP16737651.6A patent/EP3244968B1/en active Active
- 2016-01-08 NZ NZ733451A patent/NZ733451A/en unknown
- 2016-01-08 JP JP2017536934A patent/JP6890540B2/ja active Active
-
2017
- 2017-07-05 IL IL253325A patent/IL253325A0/en unknown
-
2019
- 2019-04-11 US US16/381,128 patent/US20200069658A1/en not_active Abandoned
-
2021
- 2021-05-11 US US17/317,274 patent/US20210267951A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR112017014914B1 (pt) | 2023-11-14 |
AU2016207046B2 (en) | 2021-04-01 |
JP6890540B2 (ja) | 2021-06-18 |
KR20170103918A (ko) | 2017-09-13 |
US20180325875A1 (en) | 2018-11-15 |
EP3244968B1 (en) | 2023-08-30 |
IL253325A0 (en) | 2017-09-28 |
US20200069658A1 (en) | 2020-03-05 |
CA2973114C (en) | 2023-04-04 |
NZ733451A (en) | 2023-02-24 |
CN107427698A (zh) | 2017-12-01 |
KR102569428B1 (ko) | 2023-08-21 |
EP3244968A4 (en) | 2018-09-12 |
JP2018502126A (ja) | 2018-01-25 |
WO2016114993A1 (en) | 2016-07-21 |
MX2017009110A (es) | 2017-11-09 |
RU2017128481A3 (pt) | 2019-06-25 |
EP3244968A1 (en) | 2017-11-22 |
RU2017128481A (ru) | 2019-02-14 |
US20210267951A1 (en) | 2021-09-02 |
CA2973114A1 (en) | 2016-07-21 |
AU2016207046A1 (en) | 2017-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018003588A1 (es) | Uso de inhibidores de miostatina y terapias de combinación. | |
BR112018004620A2 (pt) | moduladores da expressão de kras | |
BR112015020466A2 (pt) | inibidores de cdc7 | |
CL2017002904A1 (es) | Métodos y kits para tratar la depresión | |
EA201790398A1 (ru) | Способы лечения заболевания печени | |
BR112014021498A2 (pt) | composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado | |
EA201690980A1 (ru) | Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака | |
BR112015016466A2 (pt) | método para o tratamento de câncer baseado no estado de mutação de k-ras | |
BR112015022047A2 (pt) | métodos para tratar câncer de bexiga | |
BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
BR112015023439A2 (pt) | combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
BR112017009552A2 (pt) | métodos para alvejar o controle transcricional em regiões de super-realçador | |
EA201891514A1 (ru) | Комбинированная терапия ингибитором бромодомена и экстратерминального белка | |
BR112015018360A2 (pt) | terapia de combinação para o tratamento de pneumonia nosocomial | |
BR112019003533A2 (pt) | terapia de combinação com inibidores de glutaminase | |
BR112016007462A2 (pt) | fitonutrientes anti-inflamatórios para uso no tratamento ou prevenção de sinovite | |
BR112017014914A2 (pt) | terapia combinada para hipertensão pulmonar | |
PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
CO2022000270A2 (es) | Inhibidores de enzimas | |
BR112018073553A2 (pt) | medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. | |
WO2019043176A3 (en) | HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY | |
BR112019004791A2 (pt) | tratamento de esclerose múltipla com chs-131 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/01/2016, OBSERVADAS AS CONDICOES LEGAIS |